EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prenatal and progressive coenzyme Q 10 administration to mitigate muscle dysfunction in mitochondrial disease

Juan Diego Hernández-Camacho iD, Cristina Vicente-García iD, Lorena Ardila-García, Ana Padilla-Campos, Guillermo López-Lluch iD, Carlos Santos-Ocaña iD, Peter S Zammit iD, Jaime J Carvajal iD, Plácido Navas iD, Daniel J M Fernández-Ayala iD

Journal of Cachexia, Sarcopenia and Muscle · 2024

DOI: 10.1002/jcsm.13574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Juan Diego Hernández-Camacho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centro Andaluz de Biología del Desarrollo-CSIC, Universidad Pablo de Olavide, Seville, Spain. Hauptthemen laut MEDLINE: Ubiquinone, Mitochondrial Diseases, Muscle, Skeletal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Spanish Ministry of Education, Culture and Sports, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ADCK genes encode aarF domain‐containing mitochondrial kinases involved in coenzyme Q (CoQ) biosynthesis and regulation. Haploinsufficiency of ADCK2 in humans leads to adult‐onset physical incapacity with reduced mitochondrial CoQ levels in skeletal muscle, resulting in mitochondrial myopathy and alterations in fatty acid β‐oxidation. The sole current treatment for CoQ deficiencies is oral administration of CoQ 10 , which causes only partial recovery with postnatal treatment, underscoring the importance of early diagnosis for successful intervention.

Methods

We used Adck2 heterozygous mice to examine the influence of this gene on muscle structure, function and regeneration throughout development, growth and ageing. This investigation involved techniques including immunohistochemistry, analysis of CoQ levels, mitochondrial respiratory content, muscle transcriptome analysis and functional tests.

Results

We demonstrated that Adck2 heterozygous mice exhibit defects from embryonic development, particularly in skeletal muscle (1102 genes deregulated). Adck2 heterozygous embryos were 7% smaller in size and displayed signs of delayed development. Prenatal administration of CoQ 10 could mitigate these embryonic defects. Heterozygous Adck2 mice also showed a decrease in myogenic cell differentiation, with more severe consequences in ‘aged’ mice (41.63% smaller) ( P < 0.01). Consequently, heterozygous Adck2 mice displayed accelerated muscle wasting associated with ageing in muscle structure ( P < 0.05), muscle function (less grip strength capacity) ( P < 0.001) and muscle mitochondrial respiration ( P < 0.001). Furthermore, progressive CoQ 10 administration conferred protective effects on mitochondrial function ( P < 0.0001) and skeletal muscle ( P < 0.05).

Conclusions

Our work uncovered novel aspects of CoQ deficiencies, revealing defects during embryonic development in mammals for the first time. Additionally, we identified the gradual establishment and progression of the deleterious Adck2 mouse phenotype. Importantly, CoQ 10 supplementation demonstrated a protective effect when initiated during development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UbiquinoneMitochondrial DiseasesMuscle, SkeletalAnimalsMiceDisease Models, AnimalFemaleHumans

Stichwörter der Autor:innen

ageingcoenzyme Qdevelopmentmitochondriasatellite cellskeletal muscle

Substanzen

Ubiquinonecoenzyme Q10

Autor:innen und Institutionen

  • Centro Andaluz de Biología del Desarrollo-CSIC, Universidad Pablo de Olavide, Seville, Spain.
  • CIBERER, Instituto de Salud Carlos III, Madrid, Spain.
  • Randall Centre for Cell and Molecular Biophysics, King's College London, London, UK.

ORCID-Profile: Juan Diego Hernández-Camacho, Cristina Vicente-García, Guillermo López-Lluch, Carlos Santos-Ocaña, Peter S Zammit, Jaime J Carvajal, Plácido Navas, Daniel J M Fernández-Ayala

Förderung

  • Instituto de Salud Carlos III
  • Spanish Ministry of Education, Culture and Sports
  • Ministerio de Ciencia e Innovación
  • Junta de Andalucia
  • Friends of FSH Research
  • FSHD Society
  • Universidad Pablo de Olavide/CBUA
  • Medical Research Council

Zitieren

APA

Hernández-Camacho, J. D., Vicente-García, C., Ardila-García, L., Padilla-Campos, A., López-Lluch, G., Santos-Ocaña, C., Zammit, P. S., Carvajal, J. J., Navas, P., & Fernández-Ayala, D. J. M. (2024). Prenatal and progressive coenzyme Q 10 administration to mitigate muscle dysfunction in mitochondrial disease. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13574

Vancouver

Hernández-Camacho JD, Vicente-García C, Ardila-García L, Padilla-Campos A, López-Lluch G, Santos-Ocaña C, et al. Prenatal and progressive coenzyme Q 10 administration to mitigate muscle dysfunction in mitochondrial disease. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13574

BibTeX
@article{HernndezCamacho2024,
  author = {Hernández-Camacho, Juan Diego and Vicente-García, Cristina and Ardila-García, Lorena and Padilla-Campos, Ana and López-Lluch, Guillermo and Santos-Ocaña, Carlos and Zammit, Peter S and Carvajal, Jaime J and Navas, Plácido and Fernández-Ayala, Daniel J M},
  title = {Prenatal and progressive coenzyme Q 10 administration to mitigate muscle dysfunction in mitochondrial disease},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  doi = {10.1002/jcsm.13574}
}
Kostenlos starten →